Sales & Marketing

What’s changing in post-pandemic HCP access? Veeva’s vice president of global business consulting unveils the latest data.

Q&A addresses patient care and leads to digital solutions like telehealth as a strong delivery vehicle and an opportunity for marketers.

"AH-ha!™ It's Acne Hormones" features people affected by acne and highlights "AH-ha" moments to "pop" common acne myths and misconceptions.

Launch Ready from Day One is designed to empower a company's customer facing teams to drive demand, simplify access, and create a seamless and more integrated customer experience.

New structure strengthens offerings and drives the addition of diversified marketing services.

Adding more than 100 employees to its team in 2022, the company's growth has outpaced growth in the broader healthcare advertising segment, as pharmaceutical marketers increasingly embrace digital advertising, particularly on CTV.

Indegene expands on significant presence by adding to existing UK, Ireland, and Switzerland centers.

What the c-suite should consider in today’s marketplace.

The parameters governing pharma promotional speech in digital and social media have struggled to keep pace with the rapidly evolving healthcare communications landscape. How can FDA play catch-up in advancing an agenda more reflective of industry and patient needs?

As they are forced to do more with less, pharma commercial leaders should rethink their incentive programs to ensure their sales teams remain strong drivers of growth.

"The customer is always right" — a commitment to omnichannel marketing is a commitment to serving the customer. David Laros of Beghou Consulting offers up this tersely written playbook on the topic.

The Anglo-Swedish drugmaker on Monday agreed to pay $26 per CinCor share in cash, or $1.3 billion in total, a premium of nearly 121% to the U.S.-based company's closing price on Friday.

Fran Pollaro chats with with Indegene's Timothy Moore, Senior Vice President, Emerging Biotech and Key Accounts and Jack Mycka, Vice President, Enterprise Medical Solutions and Emerging Biotech.

Using market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.

Angie Lindsey, vice president of marketing, Fresenius Kabi USA shares 2023 strategies for talent management strategies in life sciences, specifically as it relates to sales and marketing.

Marchesini will serve as Senior Vice President to help life sciences companies improve the effectiveness and efficiency of their commercial processes and go-to-market approach.

Katya Petrova will be responsible for providing JUICE clients with direction and oversight from inception through execution.

Amgen spending big to dive deeper into rare disease treatments through deal for drugmaker Horizon Therapeutics.

Inc. 2022 Best in Business Award marks health-focused TogoRun's second year as an independent, woman-owned agency.

Built on Algorand, and in partnership with the Government of Maharashtra in India, NFT technology will be used for storing personal health data for the first time.

Brand Institute, naming agency, shares insights on emerging clinical trial naming trends.

The move bolsters Evoke’s digital innovation and omnichannel offering.

Whether pharma or FDA, healthcare outreach more visible than ever.

Over half of life sciences companies are not fully optimizing HCP engagement, according to the study.

Tech company Evermed provides modular content hubs that power personalized video content delivery for life science companies and HCPs.

The initiative taps global social influencers and shares resources, so young men can better understand the benefits of therapy.

The transaction allows TherapeuticsMD to recapitalize and transform into a pharmaceutical royalty company while giving Mayne Pharma exclusive U.S. commercialization rights for their products.

CVS is testing a system that allows pharmacists to process prescriptions remotely to help address pharmacist shortage.

Roku's Chris Schneider discusses how pharmaceutical marketers are still missing a huge population: the cord cutters.

Pfizer CEO Albert Bourla, Ph.D., is in trouble for "misleading" and "overly promotional" claims he made during a BBC interview late last year about their COVID-19 vaccine for younger kids, which was not approved at the time.